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Abstract
Targeting the estrogen receptor is an important strategy in breast cancer therapy. However, although inhibiting estro-
gen receptor function with specific estrogen receptor modulators can achieve a primary response in cancer patients,
intrinsic or subsequently acquired resistance to the therapy remains a major obstacle in the clinic. Thus, it is critical to
gain amore thorough understanding of how estrogen receptor functions are regulated in breast cancer. Here,we dem-
onstrate that the non–receptor tyrosine kinase c-ABL is a functional partner of the estrogen receptor, as expression of
c-ABL sustained transcriptional activity of the estrogen receptor. More importantly, inhibition of c-ABL resulted in sen-
sitization to treatment by tamoxifen (TAM) in estrogen receptor–positive breast cancer cells, asmanifestedby inhibition
of cell survival and suppression of anchorage-independent growth.We found that c-ABL interactswith estrogen recep-
tor in breast cancer cells and that expression of c-ABL is a frequent event in primary breast cancer tumor tissues. In
estrogen receptor–positive tumors, the expression of c-ABL significantly correlated with disease progression and me-
tastasis. This study shows that c-ABL regulates the cellular response to TAM through functional interaction with the
estrogen receptor, which suggests c-ABL as a therapeutic target and a prognostic tumor marker for breast cancer.
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Introduction
The steroid hormone estrogen receptor α (ERα, hereafter referred to
as ER) is a nuclear receptor that exerts a profound influence on the
initiation and progression of breast cancer by regulating cell transfor-
mation, proliferation, and metastasis. It is estimated that approxi-
mately 70% of breast cancer cases are ER-positive and that their
growth and progression are likely dependent on estrogen stimulation.
For ER-positive breast cancer patients, systemic antihormonal ther-
apy, such as tamoxifen (TAM), is a first-line targeted treatment. Un-
fortunately, a substantial proportion of these patients are intrinsically
resistant to this therapy and a significant number of patients with
advanced disease eventually develop acquired resistance to the treat-
ment, which poses a major clinical problem [1]. Multiple mecha-
nisms including loss of ER expression, endocrine adaptation, altered
coregulatory proteins, and deregulated signal transduction can lead
to TAM resistance. For example, elevated expression of the receptor
tyrosine kinase ErbB-2 (also known as HER-2) has been correlated
with the development of TAM resistance in breast tumors and in
breast cancer cell line models [2–4]. Overexpression of ErbB-2 has
been shown to induce ligand-independent ER phosphorylation and
transcriptional activity through the mitogen-activated protein kinase
pathway [5].
The non–receptor tyrosine kinase c-ABL is a proto-oncogene with
multiple functions. It regulates a variety of cellular activities, includ-
ing regulation of cell migration, responses to oxidative stress and
DNA damage, cell proliferation, and survival [6–10]. Our knowledge
of the oncogenic potential of aberrant ABL function in humans is
primarily based on the observation that chronic myelogenous leu-
kemia and a subset of acute lymphocytic leukemia are causally as-
sociated with the oncogenic BCR-ABL fusion protein created by
chromosomal translocation involving the c-ABL and the BCR (break
point cluster) genes [11,12]. Recent findings further demonstrated
that the oncogenic activity of the ABL protein is not confined to
hematopoietic malignancies. Negative regulation of c-ABL kinase ac-
tivity was found to be impaired in non–small cell lung cancer cells,
suggesting that deregulation of c-ABL kinase contributes to the patho-
genesis of lung cancer [13]. Furthermore, activation of c-ABL kinase
activity promotes invasion of breast cancer cells [14]. Inhibition of
c-ABL activity blocks transforming phenotypes, such as cell prolifer-
ation and anchorage-independent growth, and sensitizes cancer cells
to apoptosis caused by nutrient deprivation [15]. Taken together,
these studies have identified c-ABL as a promoting factor in solid
tumors and raise the possibility that c-ABL plays an important role
in breast carcinogenesis.
In the current study, we identified a previously unrecognized path-
way involving the functional interaction between c-ABL and ER that
leads to enhanced ER activity and promotes resistance to TAM. In
addition, we provide the first evidence that the coexpression of these
two proteins may have a prognostic value for breast cancer by exam-
ining a cohort of 142 breast cancer primary tumor tissue samples.
Materials and Methods
Cell Culture and Antibodies
The cell lines T47D, BT474, and MDA-MB-231 were purchased
from American Type Culture Collection (ATCC, Manassas, VA). All
cells were grown in Dulbecco’s modified Eagle medium/F12 (1:1) with
10% fetal bovine serum, unless otherwise indicated in experiments re-
quiring phenol red–free medium and charcoal-treated serum to re-
move estrogenic factors. All the antibodies used in this study were
purchased: anti–α-tubulin (Sigma, St Louis, MO); anti–ER-α (Bethyl,
Montgomery, TX; Leica Microsystems, Bannockburn, IL). The experi-
ments of the anti–c-ABL antibodies and their vendors were as follows:
immunoblot analysis (Calbiochem, San Diego, CA), immunohisto-
chemical staining (Abcam, Cambridge, MA), immunofluorescence
staining (BD Biosciences, San Jose, CA), and immunoprecipitation
(Cell Signaling, Danvers, MA).
Luciferase Assay
Cells (5 × 104) were plated in 24-well plates and steroid-starved for
48 hours. The luciferase reporter controlled by a triplicate of the ER-
response element (pERE-Luc) was cotransfected with the pRL-TK
plasmid, which served as the internal control. Transfections were con-
ducted using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) follow-
ing the manufacturer’s instructions. Nine hours after transfection, cells
were stimulated with estrogen (1 nM), or an equal amount of control
vehicle (ethanol), for 36 hours. Luciferase assays were then carried out
using the Dual-Luciferase Assay Kit (Promega, Madison, WI).
Immunoprecipitation Analysis
Cultured cells were washed twice with ice-cold PBS. The cells
were then lysed in NETN buffer (150 mM NaCl, 1 mM EDTA
pH 8.0, 20 mM Tris pH 8.0, 0.5% NP-40, 25 mM NaF, 2 mM
Na3VO4, 20 μl/ml aprotinin, and 0.1 M PMSF) on ice for 30 min-
utes. For immunoprecipitation, the lysate was incubated with primary
antibody at 4°C overnight. The immunocomplexes were then incu-
bated with 50 μl of protein G agarose (Roche, Indianapolis, IN) at
4°C for 2 hours. The beads were washed four times with ice-cold
NETN buffer, and the protein complexes were then eluted by boiling
the beads in 40 μl of 2× loading buffer.
Anchorage-Independent Growth Assays
Bottom-layer agar was 0.7% agarose in normal medium with 10%
FBS. Tumor cells were seeded in top soft agar of 0.35% agarose in
normal medium containing 10% FBS. Normal medium containing
10% FBS with and without TAM was then placed on top of the so-
lidified agar in each well. After approximately 3 weeks, tumor cell
colonies in an entire well were counted, with three replicate wells
per treatment, by using the ImageQuant TL software (GE Health Life
Sciences, Piscataway, NJ). Colonies sized 150 μm or greater in diame-
ter were counted.
Confocal Microscopy
Cultured cells were fixed and permeabilized with 4% formal-
dehyde and 0.2% Triton X-100 for 10 minutes at room temperature.
After four washes with PBS, the cells were blocked with 10% normal
goat serum for 1 hour at room temperature, and then immuno-
stained with primary antibodies (1:200 dilution in PBS with 0.2%
BSA) overnight at 4°C. Cellular c-ABL was detected with mouse
monoclonal antibody (BD Biosciences), whereas ER was detected
by a rabbit polyclonal antibody (Bethyl). After three washes with
PBS, the FITC- or Texas Red–conjugated secondary antibody was
applied for 45 minutes at room temperature. Nuclei were stained
with TOPRO 3. Images were captured with a Zeiss laser scanning
confocal microscope (LSM510).
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Tissue Samples and Tumor Microarray
One hundred and forty-two formalin-fixed, paraffin-embedded,
archival tumor tissues from breast cancer patients enrolled at the
Cancer Center of Kaohsiung Medical University Hospital (Taiwan)
from 2005 to 2007 were included in this study (Table 1). The ethics
committee approved the study, and informed consent was obtained
from each patient. The age at diagnosis ranged from 29 to 81 years
(mean, 50.49 years) with 47.9% of the women younger than 50 years.
Histologic typing showed 83% invasive ductal carcinomas, 12% in-
filtrating lobular carcinoma, and 6% carcinoma in situ. The clinico-
pathologic features of the patients are listed in Table 1. Tumor staging
was defined according to the TNM system, and histologic typing
was determined according to the guidelines of the World Health Or-
ganization. The expression levels of ER, progesterone receptor (PR),
and ErbB-2 were obtained from the database of cancer registry from
Kaohsiung Medical University Cancer Center. The slides were read
by two pathology personnel in a double-blinded manner for c-ABL
expression, which was scored by theH-score method (product of inten-
sity and area). The H -score 0.5 was used as a cutoff for c-ABL im-
munohistochemistry (IHC; H -score < 0.5, low expression; H -score >
0.5, high expression).
Statistical Analysis
Data of each assay were expressed as means ± SD (n = 3). Statis-
tical differences between two groups were determined by Student’s
t-test. P < .05 was considered significantly different. For the IHC
study of tumor tissues, all of the statistical analyses were performed
using the statistics program SPSS11.5 for PC (SPSS, Inc, Chicago,
IL). Tumors were grouped according to c-ABL expression levels: the
high-expression group (ABL+) and the low-expression group (ABL−).
Expression levels were correlated with age group, tumor stage, tumor
grade, tumor size, lymph node status, ER status, PR status, and ErbB-2
status. The P value was determined by the χ 2 test or by Fisher’s exact
test when the sample size was less than 5. Differences with P ≤ .05
were considered statistically significant.
Gene Silencing by Short Hairpin RNA
To generate lentiviral particles capable of expressing short hairpin
RNA (shRNA) against c-ABL, luciferase, and the control of scram-
bled sequence, the corresponding shRNA was cloned in pLKO.1-
hairpin vector and was provided by the National RNAi Core Facility,
Academia Sinica, Taiwan. Recombination with the lenti-gag/pol, en-
velope, and Rev plasmids in 293T cells was conducted at the Viral Vec-
tor Core at Cincinnati Children’s Hospital. The specific sequences of
the shRNA are as follows: shABL-1 CCGGGAGTTCTTGAAGCAT-
TTCAAACTCGAGTTTGAAATGCTTCAAGAACTCTTTTTG;
shABL-2 CCGGTAATTACCGTGAG-TGACATAGCTCGAGC-
TATGTCACTCACGGTAATTATTTTTG; shLuc CCGGCAAAT-
CACAGAATCGTCGTATCTCGAGATACGACGATTCTGT-
GATTTGTTTTTG. shScramble CCTAAGGTTAAGTCGCCCTCG-
CTCTAGCGAGGGCGACTTAACCTTAGG generated by Dr. David
Sabatini’s laboratory [16]. To generate stable cell lines, cells were in-
fected with the corresponding lentivirus and selected with puromycin.
The surviving clones were then pooled for further experiments.
Combination Indices and Isobologram Analysis
Data from Cell Titer-Glo assays (Promega) were analyzed using
CalcuSyn statistical software (Biosoft, Cambridge, UK). Isobolograms
generated by CalcuSyn were based on dose-response curves for both
TAM and STI571. Data points below the line represent synergistic
drug interactions, whereas points on or above the line indicate addi-
tivity or antagonism, respectively. A combination index (CI) value of
1 indicates additivity, a CI value greater than 1 indicates antagonism,
and a CI value less than 1 indicates synergism.
Results
To examine the effect of c-ABL on ER function, we first tested whether
c-ABL regulates the transcriptional activity of ER in the breast can-
cer cell line T47D, which expresses high levels of ER and c-ABL. Cells
were infected with lentiviral vectors carrying the shRNA against c-ABL
(shABL-1 and shABL-2; two different shRNA clones) or the control
shRNA of random sequence (shScramble). Infected cells were selected
by puromycin, and the resulting stable clones were pooled for fur-
ther assays. To determine whether c-ABL regulates the transcriptional
function of ER, the shRNA-harboring T47D cells were transiently
transfected with a luciferase reporter gene controlled by the estrogen
response element (pERE-Luc) and grown in phenol red–free medium
with charcoal-treated serum. Cells were then stimulated with 17β-
estradiol or the control vehicle followed by luciferase activity assay.
Silencing of c-ABL repressed luciferase reporter activity to a level sim-
ilar to that achieved by TAM (Figure 1A), indicating that c-ABL is re-
quired for optimal activation of the reporter gene. The level of c-ABL
expression in these engineered clones has no effect on expression of the
endogenous ER protein. We then tested whether introducing c-ABL is
sufficient for activating the transcriptional function of ER. For this
Table 1. Association of c-ABL Expression with Clinicopathological Variables in Breast Cancer
Patients (N = 142).
Characteristics Total N ABL+ ABL− P *
Age (years)
<50 68 28 39 .008
≥50 74 48 26
Stage
0/I/II 108 54 54 .072
III/IV 34 23 11
Grade
1 8 5 3 .597
2 102 57 45
3 32 15 17
Tumor size (cm)
≦5 123 70 53 .284
>5 19 10 9
Lymph node status
Negative 93 48 45 .389
Positive 49 29 20
Recurrence†
No 124 69 55 .373
Yes 18 8 10
ERα status
Positive 96 55 41 .289
Negative 46 22 24
PR status
Negative 65 39 26 .204
Positive 77 38 39
ErbB-2 status
Negative 81 47 34 .387
Positive 43 25 18
ND 18 5 13
ND indicates not determined.
*χ 2 test or Fisher’s exact test.
†Median follow-up, 18 months.
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experiment, the breast cancer MCF-7 cells, which are ER-positive but
express low level of c-ABL activity [15], grown in phenol red–free me-
dium containing charcoal-treated serum were cotransfected by pERE-
Luc with c-ABL complementary DNA (cDNA) or vector control
(Figure 1B). As expected, estrogen significantly stimulated the luciferase
reporter gene activity in cells cotransfected with the control vector,
and treatment with TAM repressed the transactivation in a dose-
dependent manner. Cotransfection with the wild-type (WT) c-ABL
cDNA resulted in moderate enhancement of estrogen-mediated
reporter activation, which sustained the inhibition of up to 10 nM
of TAM treatment. The kinase-deficient (kd) mutant (K290R) of
c-ABL [17] had a similar effect on the ERE reporter, indicating that
a kinase-independent mechanism may be involved in c-ABL–mediated
ER activation. Nevertheless, transfection of the constitutively activate
(CA) mutant (P242A/P249A) of c-ABL [18] resulted in more dramatic
activation by estrogen than the WTand kd c-ABL, even in the presence
of TAM (up to 100 nM). Thus, these results support that c-ABL can
enhance the transactivation function of ER in both kinase-dependent
and -independent manners. This is in contrast to ARG (ABL-related
gene; also known as ABL2), the other member of the ABL family.
Figure 1. Depletion of c-ABL resulted in reduced ER activity in transactivation assays. (A) Parental T47D cells (Parental) and their derivatives
harboring shRNA of scrambled control sequence (shScramble) or c-Abl (shABL) were starved in estrogen-free medium for 48 hours then
transfected with the ERE-luciferase reporter in the presence or absence of estrogen (1 nM). The fold induction of the reporter was plotted,
with the activity of the parental cells set to 1. As a positive control for reduced ER activity, the parental cells were treated with TAM (Tam).
The inset shows a Western analysis of c-ABL and ER expression in the cell line used in this experiment. (B) MCF-7 cells (5 × 104) were
plated in 24-well plates in phenol red–free medium containing charcoal-treated serum (10%) for 48 hours. The cells were then transfected
with ERE-Luc along with a control vector (pcDNA3), or the cDNA of WT c-ABL (c-ABL/WT), or the kd (c-ABL/kd) or CA (c-ABL/CA) c-ABL
mutants. The plasmid pRL-TK was cotransfected in each transfection as the internal control. Nine hours after transfection, cells were
stimulated with or without estrogen (1 nM) for 2 hours, then treated with different concentrations of TAM as indicated (in the presence
of 1 nM estrogen) for 36 hours. Each data point was obtained in triplicate and the experiment was repeated for three times. *P < .05,
**P < .01, ***P < .001 (compared with the vector control). Bars, SD. (C) Same as in panel B except that the cells were transfected with
ERE-Luc along with the control vector pcDNA3 or the cDNA of WT ARG.
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Reporter assay showed that introducing ARG was not able to enhance
the estrogen-mediated ER activation in comparison with the vector
control (Figure 1C). This result indicates that the effect on ER func-
tion is unique to c-ABL in the ABL kinase family.
Prompted by these results, we proposed that c-ABL is involved in
resistance to TAM-induced growth inhibition in ER-positive breast
cancer cells. If this hypothesis is correct, silencing c-ABL expression
should result in sensitization of cell to TAM treatment. To test this hy-
pothesis, we compared the T47D/shABL cells and the isogenic control
cell line T47D/shLuc, which harbors the shRNA against the lucifer-
ase gene introduced by lentiviral vector. In addition to T47D, the
same pair was also generated for BT474 (namely BT474/shABL and
BT474/shLuc). Like T47D, BT474 is a ER-positive breast cancer cell
line expressing high levels of c-ABL (data not shown) [14]. For each
cell line, two independent c-ABL shRNA (shABL-1 and shABL-2)
were used to generate independent c-ABL–knockdown lines (Figure 2),
and there is no significant difference between the c-ABL–silenced lines
and the corresponding control lines (Figure W1). The cells were then
Figure 2. Inhibition of c-ABL resulted in sensitization of breast cancer cells to TAM treatment. Top panel: Pooled clones derived from
T47D cells harboring a shRNA against luciferase (T47D/shLuc) and two independent shRNA against c-ABL (T47D/shABL-1 and T47D/
shABL-2) were treated with TAM at the indicated concentrations for 1 week. The surviving cells were then assessed by MTT assay, and
cell survival was plotted. Western analysis showing the efficiency of shRNA silencing of c-ABL. Middle and lower panels: The same
setting for BT474 and MDA-MB-231, respectively. ***P < .001.
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cultured in medium containing different doses of TAM. Silencing
c-ABL in T47D and BT474 cells resulted in sensitization to TAM
treatment compared with the corresponding shLuc control. In con-
trast, down-regulation of c-ABL in the ER-negative c-ABL–expressing
breast cancer cell line MDA-MB-231, which is resistant to TAM due
to the lack of ER expression, did not sensitize cells to the treatment,
suggesting that the c-ABL effect was through a functional ER. In
addition to the short-term growth assay, down-regulation of c-ABL re-
sulted in a long-term sensitization to TAM-induced cell growth inhi-
bition as demonstrated by a clonogenic assay in which cells were
seeded at low density in medium with or without TAM and grown
for 2 weeks (Figure 3A). The effect of c-ABL on long-term growth
inhibition by TAM is further supported by comparing the ability of
shABL and shLuc cells in anchorage-independent growth as measured
by a colony formation assay in soft agar in the presence and absence of
TAM (Figure 3B).
These results indicate that c-ABL plays a positive role in maintain-
ing cell growth in response to TAM treatment and that inhibiting
c-ABL can sensitize breast cancer cells to treatment of antiestrogens.
To test this hypothesis, T47D cells were treated by TAM, the ABL in-
hibitor imatinib (STI571; Gleevec; LC Laboratories, Woburn, MA) or
both in combination (Figure 4A). Treatment with imatinib or TAM
alone moderately suppressed the survival of T47D cells. The suppres-
sion was significantly enhanced when TAM was combined with imati-
nib in the treatment (P < .05). To further understand the interaction
between imatinib and TAM, we performed an isobologram analysis
(Figure 4B). In this analysis, the dose-response curve of TAM alone,
imatinib alone, and different doses of TAM combined with 10 μM
of imatinib were plotted, and the CI was determined. A CI value less
than 1 indicates synergy, a CI value equals to 1 indicates addition, and a
CI higher than 1 indicates antagonism [19]. The analysis shows that
combination of TAM and imatinib has synergistic effect in T47D cells.
Similar results were observed in BT474 cells (Figure W4). Taken to-
gether, these results demonstrate a functional interaction between
c-ABL and ER in breast cancer cells to develop resistance to TAM
and suggest that simultaneously targeting c-ABL and ER can increase
therapeutic response in ER-positive breast cancer cells.
To further address the relationship between c-ABL and ER, we
examined whether these two proteins interact in vivo. To this end,
ER and c-ABL were ectopically coexpressed in HEK293T cells by
transient transfection. Pulling down c-ABL by immunoprecipitation
with an anti–c-ABL antibody also coprecipitated ER (Figure 5A, left
panel ), and vice versa (Figure 5A, right panel ), demonstrating that
these two proteins form a complex in cells. The interaction between
c-ABL and ER was further confirmed in T47D cells by reciprocal
immunoprecipitation of the endogenous proteins (Figure 5B). The
Figure 3. c-ABL is required for long-term TAM resistance. (A) In 24-well plates, 3000 cells of the indicated clones were plated in each well,
and the cells were grown for 2 weeks in medium containing 1 nM TAM. The resulting colonies were stained with crystal violet. The exper-
iment was repeated three times, and representative data are shown. (B) Left panel: The indicated T47D sublines were seeded in triplicate
in soft agar prepared in phenol red–free medium and layered with medium containing the indicated concentration of TAM and cultured for
3 weeks. Top medium was changed every three days with medium containing the indicated concentration of TAM. The colonies in the
well were then stained and counted (right panel; with 1 μM TAM). *P < .05, **P < .01 (compared with the T47D/shLuc control).
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c-ABL kinase is known to shuttle between the cytoplasm and the
nucleus [20]. Under confocal immunofluorescence microscopy colo-
calization between c-ABL and ER clearly speckled in the nucleus and
in the cytoplasm, where most c-ABL resided (Figure 5C ). Interest-
ingly, the interaction between c-ABL and ER was enhanced by TAM
(Figure 5D), which is in concordance with the notion that c-ABL
and ER interact with each other in response to TAM treatment. We
observed similar results using the BT474 cell line (Figure W3).
These results also suggest that the expression of c-ABL and ER
together may better correlate with breast cancer progression than ei-
ther marker alone. We evaluated primary tumor tissues derived from
142 archived breast cancer cases (Table 1). IHC analysis was con-
ducted to examine the expression of c-ABL in these tumor tissues
(Figure 6). The expression of c-ABL was a frequent event; this can
be observed in 54% of the tumors, and immunostaining for c-ABL
was visible in both the cytoplasm and the nucleus. Although the ex-
pression of c-ABL alone was not correlated with ER, PR, or ErbB-2
expression, or nodal involvement (Table 1), it was marginally corre-
lated with tumor stage in that the c-ABL high-expression group
tended to have more advanced disease than the c-ABL low-expression
group (30% vs 17%, P = .072). This trend turned into a significant
correlation when both c-ABL and ER expression were considered,
in which 38.2% of the c-ABL(+)/ER(+) tumors were at an advanced
stage, as opposed to only 7.3% of the c-ABL(−)/ER(+) tumors (P =
.001; Figure 6B). In addition, 43.6% of the tumors in the c-ABL(+)/
ER(+) group had lymph node involvement, as compared with the
c-ABL(−)/ER(+) group, which included only 19.5% of the tumors
(P = .019; Figure 6C ). Collectively, these results suggest that simul-
taneous expression of c-ABL and ER promotes disease progression
and metastasis.
Discussion
ER function has a profound impact on the outcome of breast cancer.
On one hand, ER expression is correlated with a favorable prognosis,
partly because of its potential to confer responsiveness to hormonal
therapy. Conversely, ER is a well-established neoplastic factor in pro-
moting proliferation of breast cancer cells. In this study, we showed
that c-ABL functionally interacted with ER in regulating the cellular
response to TAM and in breast cancer progression. This is based on
the observations that c-ABL is required for maintaining ER transcrip-
tional activity and that silencing c-ABL results in the sensitization of
ER-positive but not ER-negative breast cancer cells to TAM treat-
ment. In addition, our immunoprecipitation study demonstrated that
c-ABL and ER form a complex in breast cancer cells and the asso-
ciation is enhanced by TAM treatment. This observation raises the
question of whether the change of c-ABL–ER association is also ac-
companied with alteration in the complex formation of ER with
its other transcriptional coregulators. Previous studies have shown
that aberrant regulation of ER resulted in the recruitment of coac-
tivators and converted TAM to an estrogenic rather than antiestro-
genic factor in breast cancer cells [5]. In our cohort of human breast
cancer cases, positive c-ABL expression was a frequent event. More-
over, coexpression of c-ABL and ER in tumors was significantly
correlated with late-stage breast cancer (P = .001) and nodal involve-
ment (P = .019), an indication of cancer cell dissemination. The
Figure 4. Targeting c-ABL activity sensitizes breast cancer cells to TAM treatment. (A) T47D cells were treated with control vehicle alone
(C) (white bars), 1 μM of TAM (T) or 10 μM imatinib (I) alone (gray bars), or in combination (black bars) as indicated for 6 days, and the
effect on cytotoxicity was measured by the CellTiter-Glo kit (Promega). The data are derived from three independent experiments. *P <
.05, compared with TAM treatment alone. (B) Normalized isobologram produced by the software CalcuSyn in T47D cells. A represen-
tative plot is shown. Values below the threshold line indicate synergistic combination. Table shows the CIs of different doses of TAM
with 10 μM of imatinib derived from three independent experiments.
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group of patients included in this study was enrolled within a 2-year
period, hence the information on their response to antihormonal
therapy would require further follow-up. Nonetheless, our study re-
veals a novel functional interaction between c-ABL and the nuclear
hormonal receptor ER in breast cancer development. This observa-
tion is likely to be translated into a therapeutic gain as treatment with
the clinically approved ABL inhibitor imatinib sensitizes breast can-
cer cells to TAM.
Unlike T47D, MCF-7 cells express low levels of c-ABL activity.
Although introducing the WT, kd, and CA forms of c-ABL all re-
sulted in enhanced ER activity, the CA c-ABL mediated a more pro-
nounced activation of ER activity compared with the WTand the kd
mutant, indicating that the kinase activity of c-ABL plays an impor-
tant role in ER regulation. The observation that both WT and the
kd mutant c-ABL have similar effects on ER activity may be because
c-ABL kinase activity is subject to negative regulation by autoinhibi-
tion [21,22]. It should be noted that the WT and kd c-ABL cDNA
expressed equal levels of c ABL in MCF-7 cells (Figure W2). Thus,
the CA mutant, which is not subject to the autoinhibition, exhibited
the strongest activation effect on ER through a kinase-dependent
mechanism. Conversely, the observation that both the WT and the
kd mutant c-ABL induced a moderate increase in ER activity sug-
gests that c-ABL can also activate ER function through a kinase-
independent mechanism. Such a mode of c-ABL activity has been
documented previously [23]. Consistently, the interaction between
c-ABL and ER was independent of the kinase activity of c-ABL be-
cause the kd c-ABL mutant interacted with ER as strongly as the WT
c-ABL (data not shown).
The functional collaboration between c-ABL and ER resembles
the cross talk between ErbB-2 and ER. Coexpression of ErbB-2
and ER tends to occur in high-grade lesions, and elevated ErbB-2
expression correlated with enhanced resistance to antihormonal ther-
apy and a poor outcome in ER-positive patients [4], possibly because
the activation of ErbB-2 signaling stimulates the intrinsic activity of
ER and activates the nuclear coactivator [5,24]. While this work was
in progress, Oh et al. [25] reported that c-ABL physically interacted
with and phosphorylated the nuclear receptor coactivator AIB1, re-
sulting in enhanced ER activation and cell growth on estrogen stim-
ulation. This is in agreement with the results of our study in which
we further demonstrated that c-ABL interacts with ER, sustains its
transcriptional function on TAM treatment, and enhances cellular
resistance to TAM. Furthermore, our study identified c-ABL expres-
sion as a previously unrecognized tumor marker in breast cancer. Co-
expression of c-ABL and ER constitutes a molecular signature that
correlates with advanced disease progression and metastasis. Thus,
the cellular outcome of ER expression in cancer development seems
to depend on the molecular makeup of the tumor, such as the status
of its modulator c-ABL, and the pathophysiological consequence of
c-ABL expression in breast tumors may also depend on the function
of other factors such as ER.
Figure 5. ER and c-ABL form a protein complex in vivo. (A) Transient transfection in 293T cells. Left panel: 293T cellswere cotransfectedwith
cDNA for ER-α and c-ABL. The cell lysates were then immunoprecipitated with an anti–c-ABL antibody or a control immunoglobulin class G.
After gel separation, the coprecipitated ER and c-ABL were detected by using the corresponding antibodies. Right panel: The reciprocal ap-
proach after immunoprecipitation of ER. (B) Interaction of endogenousER and c-ABLproteins in T47D cells by immunoprecipitationwith anti–
c-ABL (left panel) and anti-ER (right panel) antibodies, respectively.HC indicates heavy chain. (C) Colocalization of cellular ER (green) and c-ABL
(red) in T47D cells by confocal immunofluorescence. The inset shows the amplified viewof the area circledby thedotted square. Arrowspoint
to examples of colocalization indicated by yellow fluorescence. The nuclei were stained blue with TOPRO 3. Bar, 10 μm. (D) The interaction
betweenendogenousERand c-ABL is enhancedbyTAM. T47Dcellswere treatedwith TAM (Tam, 1μM)or ethanol as the control vehicle (Ctrl)
for 6 hours. Cell lysateswere then subjected to immunoprecipitationwith theanti–c-ABLantibody. Left panel: Thecellular ERpulleddownwas
detected by Western analysis. Right panel: Data were quantitated and normalized with respect to immunoprecipitated c-ABL.
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Our study suggests that c-ABL could be used as a prognostic
marker and a treatment target of breast cancer. Like ErbB-2, coex-
pression of c-ABL with ER may render the nuclear receptor under
the control of the tyrosine kinase. Thus, markers such as c-ABL
and ErbB-2 may also assist in determining appropriate therapeutic
approaches targeting tumors resistant to antiestrogen treatments.
Further study will be needed to dissect how the c-ABL kinase regu-
lates the tumor’s response to hormonal therapy and whether cotarget-
ing of ER and c-ABL can yield improved clinical outcome.
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Figure W1. Morphology and growth characterization of T47D and BT474 cell clones used in the study. (A) Cell morphology under light
microscope (5× amplification) of the cell lines indicated. (B) Cell viability determined by Trypan blue analysis. (C) Flow cytometry analysis
for the cell cycle status of the indicated cell lines.
Figure W2.MCF-7 cells transfectedwith the control vector (pcDNA3),
or the cDNA ofWT c-ABL (c-ABL/WT), or the kd (c-ABL/kd) c-ABLmu-
tants as indicated in Figure 1. The cells were cultured for 3 days and
subject to G418 selection (500 μg/ml) for 2 weeks to enrich the trans-
fected cells. The pooled cell clones were then lysed, and the expres-
sion level of c-ABL and the endogenous level of tubulin were then
determined by Western analysis.
Figure W3. Interaction between c-ABL and ER in BT474 cells. (A) ER and c-ABL are colocalized in BT474 cells by confocal immunoflu-
orescence microscopy as described in Figure 5C . Arrows indicate examples of colocalization (yellow). (B) The interaction is enhanced by
TAM treatment, which is demonstrated by immunoprecipitation of c-ABL as described in Figure 5D.
Figure W4. Targeting c-ABL activity sensitizes breast cancer cells to TAM treatment. (A) BT474 cells were treated with control vehicle
alone (C) (white bars), 5 μM of TAM (T) or 10 μM imatinib (I) alone (gray bars), or in combination (black bars) as indicated, and the effect
on cell growth was measured by the CellTiter-Glo kit (Promega). *P < .05 compared with TAM treatment alone. Similar results were
obtained by MTT assays (data not shown). (B) A representative isobologram analysis of the TAM-imatinib combination in BT474 cells.
The result indicates that in combination with 10 μM of imatinib, the combination of TAM and imatinib yields either a synergistic or an
additive activity.
